The Iminosugar AMP-DNM Improves Satiety and Activates Brown Adipose Tissue Through GLP1

Obesity is taking on worldwide epidemic proportions, yet effective pharmacological agents with long-term efficacy remain unavailable. Previously, we designed the iminosugar N-adamantine-methyloxypentyl-deoxynojirimycin (AMP-DNM), which potently improves glucose homeostasis by lowering excessive glyc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes (New York, N.Y.) N.Y.), 2019-12, Vol.68 (12), p.2223-2234
Hauptverfasser:	Herrera Moro Chao, Daniela, Wang, Yanan, Foppen, Ewout, Ottenhoff, Roelof, van Roomen, Cindy, Parlevliet, Edwin T, van Eijk, Marco, Verhoek, Marri, Boot, Rolf, Marques, Andre R, Scheij, Saskia, Mirzaian, Mina, Kooijman, Sander, Jansen, Kirstin, Wang, Dawei, Mergen, Clarita, Seeley, Randy J, Tschöp, Matthias H, Overkleeft, Herman, Rensen, Patrick C N, Kalsbeek, Andries, Aerts, Johannes M F G, Yi, Chun-Xia
Format:	Artikel
Sprache:	eng
Schlagworte:	1-Deoxynojirimycin - analogs & derivatives 1-Deoxynojirimycin - pharmacology Adamantane - analogs & derivatives Adamantane - pharmacology Adipose tissue (brown) Adipose Tissue, Brown - drug effects Animals Brain - drug effects Brain - physiology Glucagon Glucagon-like peptide 1 Glucagon-Like Peptide 1 - physiology Glucose - metabolism Glycosphingolipids Homeostasis Male Mice Mice, Inbred C57BL Obesity Obesity - drug therapy Obesity - metabolism Rats Rats, Wistar Satiation - drug effects Satiety Secretion Signal Transduction - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!